On the 24th, Kukje Pharma (CEO Tae-Hoon Nam) announced that it has signed a co-promotion agreement with UK CHEMIPHARM (CEO Ki-Beom Oh).
Under the agreement, Kukje Pharma will jointly promote and distribute five products from UK CHEMIPHARM’s UK Kit lineup, which includes:
These products will be marketed under the unified name "UK Kit Injection".
This collaboration aims to contribute to public health by expanding the use of integrated sterile antibiotic kits in medical institutions, thereby enhancing infection prevention and control, while also driving business growth for both companies.
UK Kit Injection is Korea’s first integrated sterile antibiotic kit product, enabling aseptic compounding. It is specifically designed for infection control and prevention.
The product has been highly regarded for improving both safety and convenience, as it helps prevent needlestick injuries among healthcare professionals and allows for rapid preparation.
This type of integrated injection is categorized as a Ready-To-Use Product (RTUP), a formulation widely adopted in general hospitals across the U.S., Europe, and Japan.
Through this agreement, the two companies plan to actively promote the product’s infection-prevention benefits and economic advantages?such as improved workforce efficiency?to hospital and healthcare decision-makers. They also aim to pursue further collaboration opportunities to expand their market presence.
Choi Min-Young, Executive Vice President and COO of UK CHEMIPHARM, stated,
“Through this co-promotion, we expect the partnership to help raise awareness of these clinically valuable products and deliver real benefits to both hospitals and patients.”
Kim Young-Gwan, Executive Vice President and CTO of Kukje Pharma, added,
“We intend to fully leverage our sales capabilities to promote the strengths of UK Kit Injection, focusing on hospitals that have not yet adopted the product, to ensure it reaches more medical institutions and benefits more patients.”